Australian biotech company Starpharma announces positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel
- Written by PR Newswire
MELBOURNE, Australia, Nov. 26, 2021 /PRNewswire/ -- Starpharma showed that 100% of evaluable patients with Stage IV prostate cancer have had efficacy responses, utilising one or more standard measures of disease.
DEP® cabazitaxel is a patented, detergent (polysorbate-80[1])-free, nanoparticle version of the conventional cancer drug,...
